Status:
COMPLETED
A Safety Study of LY2811376 Single Doses in Healthy Subjects
Lead Sponsor:
Eli Lilly and Company
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
20-65 years
Phase:
PHASE1
Brief Summary
This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2811376 single doses, how the body handles the drug, and the drug's effect on the body.
Detailed Description
This is a Phase 1 study with 2 parts, both in healthy subjects. Part 1 is a subject- and investigator-blind, placebo-controlled, randomized, 3 period, crossover study. Part 1 will assess the safety an...
Eligibility Criteria
Inclusion
- Healthy men and nonchild-bearing potential women
- 20 years or older
- Body mass index between 18-32kg/m2
Exclusion
- Taking over-the-counter or prescription medication with the exception of vitamins or minerals or stable doses of thyroid or estrogen hormone replacement.
- Smoke more than 10 cigarettes per day.
- Consume more than 5 cups of coffee per day.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00838084
Start Date
December 1 2008
End Date
June 1 2009
Last Update
July 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Glendale, California, United States